Getting a stronger foothold in the cardiovascular therapeutic area, Kos Pharmaceuticals Inc. paid $104 million in cash to Biovail Corp. for U.S. sales and marketing rights to Cardizem LA. (BioWorld Today)

Genmab A/S partnered a preclinical project in organ transplant rejection and T-cell mediated disorders, HuMax-TAC, with Serono SA in a deal that could be worth up to $40 million in up-front and milestone payments, plus royalties on eventual product sales. (BioWorld International)